Visudyne Manufacturer QLT Must Pay Sales Royalties To AMD Therapy Patent Inventors
This article was originally published in The Pink Sheet Daily
Executive Summary
Court must still decide whether Massachusetts Ear and Eye Infirmary, which won the patent case, is entitled to payments on past sales of the Novartis-marketed eye treatment.
You may also be interested in...
OSI Puts Eye Disease Franchise On The Market
Ongoing Macugen trials look promising, but OSI chooses to put its R&D funds into diabetes and oncology businesses, CEO tells analysts.
Lucentis’ First Patients Mostly Taken From Macugen, Visudyne & Avastin – Genentech
The company recorded $153 mil. in sales for the macular degeneration product in its first full quarter on the market.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.